MedTrace Logo

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

NCT02891161 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-11-27

Study results available
· View outcomes & findings →

Summary

This is an open label, multi-institutional, single arm study of a phase Ib study, followed by a phase II study of durvalumab with radiation therapy (RT) in patients with urothelial cancer (UC). No randomization or blinding is involved.

Conditions

Interventions

DRUG

durvalumab

1500 mg Q4 weekly

RADIATION

Radiation Therapy

64.8 Gy, 36 daily fractions on weekdays over about 7 weeks

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Monika Joshi, MD

    lead OTHER

Principal Investigators

  • Monika Joshi, MD, MRCP · Penn State Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-16
Primary Completion
2019-08-06
Completion
2022-04-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02891161 on ClinicalTrials.gov